Anúncio
Anúncio

TVRD

T

Tvardi Therapeutics, Inc. Common Stock

4.60
USD
Patrocinado
+0.37
+8.72%
09 de jan., 12:44 UTC -5
Abrir

Relatórios de Lucros TVRD

Rácio de surpresa positiva

TVRD separação 20 de 39 últimas estimativas.

51%

Próximo Relatório

Data do Próximo Relatório
09 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.65
Mudanças implicadas de Q3 25 (Revenue/ EPS)
--
/
+10.17%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
--
/
--

Tvardi Therapeutics, Inc. Common Stock earnings per share and revenue

On 13 de nov. de 2025, TVRD reported earnings of -0.59 USD per share (EPS) for Q3 25, beating the estimate of -1.01 USD, resulting in a 42.14% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.95% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analistas forecast an EPS of -0.65 USD, with revenue projected to reach -- USD, implying an aumentar of 10.17% EPS, and aumentar of 0.00% in Revenue from the last quarter.
FAQ
For Q3 2025, Tvardi Therapeutics, Inc. Common Stock reported EPS of -$0.59, beating estimates by 42.14%, and revenue of $0.00, 0% as expectations.
The stock price moved down -1.95%, changed from $4.11 before the earnings release to $4.03 the day after.
The next earning report is scheduled for 09 de mar. de 2026.
Based on 10 analistas, Tvardi Therapeutics, Inc. Common Stock is expected to report EPS of -$0.65 and revenue of -- for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio